Quality in Sport
January 26, 2026
Adam Wolski, Ewa Szplit, Mikołaj Franciszek Patalong et al.
Background: Psychedelic substances have been used for millennia in religious and healing contexts and have recently re-emerged as subjects of scientific interest due to advances in neuroscience and psychiatry. Research suggests that psychedelics may address limitations of conventional psychiatric treatments, particularly in disorders such as major depressive disorder, PTSD, substance use...
Mental Health Weekly
January 23, 2026
Valerie A. Canady
Microdosing — once a niche practice whispered about in online forums and tech circles — has firmly entered the mainstream. A new RAND survey suggests that millions of U.S. adults are now taking sub‐perceptual amounts of psychedelics such as psilocybin, LSD and MDMA, often with goals that differ sharply from those associated with traditional, full‐dose use.
African journal of alcohol and drug abuse.
January 22, 2026
Morris Kamenderi, John Muteti, Stephen Kimani et al.
Drugs and substance use among university students has been recognized as a global public health issue. Adolescents are particularly vulnerable to drugs and substance use (DSU) including addiction.This study sought to determine the burden of DSU among university students in Kenya. The study utilized a cross-sectional study design covering a representative sample of 17 public and private...
Federal Sentencing Reporter
January 22, 2026
Laura I. Appleman
1 citation
Abstract The shifting legal landscape of drug regulation in the United States has been marked by a growing divergence between state and federal approaches to cannabis and psychedelics. In recent years, numerous states have passed laws legalizing or decriminalizing marijuana and exploring the therapeutic potential of psychedelics, such as psilocybin and MDMA. At the same time, these trends are...
Edward Elgar Publishing eBooks
January 20, 2026
Muireann Quigley, Matt Hayler
In this chapter, we consider the therapeutic potential of psychedelics, such as psilocybin and midomafetamine (MDMA), as a novel response to deepening mental health crises. In particular, we examine this in the context of restrictive drug control systems across Europe (including the United Kingdom). Whilst promising results from several clinical studies have fed into and helped to perpetuate a...
CNS Drugs
January 17, 2026
Gaëlle Rached, Anna Campana, Dimitri Fiani et al.
1 citation
Monoamine oxidase inhibitors (MAOIs) remain an important option for patients with treatment-resistant depression (TRD) and other psychiatric conditions, despite potentially serious drug-drug interactions and associated dietary tyramine restrictions. However, they are rarely prescribed in patients with comorbid substance use disorders (SUDs) due to concerns about potential drug interactions and...
medRxiv
January 16, 2026
Kristian Larsen, Patrick M. Fisher, Drummond E. Mcculloch et al.
1 citation
preprint
Classical psychedelics have regained interest for their potential to treat psychiatric and neurological disorders, and explore neural mechanisms supporting perception, cognition, and mood. Acute psychedelic effects have been linked to increases in brain complexity and entropy, but it is unclear if these changes are specific to psychedelics or reflect more general psychoactive effects. Here, we...
Molecules
January 9, 2026
Anna Trynda, Katarzyna Karwowska, Weronika Karpowicz et al.
Synthetic cathinones are cathinone analogues that humans have artificially created. The first compounds appeared on the European market in 2005. They belong to a class of drugs called stimulants, classified as new psychoactive substances. Synthetic cathinones are very popular; people use these drugs because they are cheaper "substitutes" for other stimulants. They produce psychostimulant and...
ACS Chemical Neuroscience
January 7, 2026
Charalampos L. Kandilakis, Costas Papatheodoropoulos
Psychedelics are a diverse class of psychoactive compounds that profoundly alter perception, cognition, and emotional states. Recently, classical serotonergic agents, such as psilocybin and lysergic acid diethylamide (LSD), along with atypical agents such as methylenedioxymethamphetamine (MDMA, ecstasy) and ibogaine, have attracted renewed attention due to their rapid and sustained clinical...
The Journal of Sex Research
January 5, 2026
Lauren A Smith, Katerina Z Kolokotroni, Rhys Turner-Moore
There is limited research on how substance use impacts people's freedom to negotiate sexual activity with others, particularly in distinguishing between alcohol and drug use. This study addressed that gap by exploring how substance use can both extend and constrain sexual negotiation. A mixed-methods online survey of 354 UK adults aged 18-40 examined sexual consent across sober, alcohol-, and...